

S63845

Catalog No: tcsc6420



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1799633-27-4

Formula:

$C_{39}H_{37}ClF_4N_6O_6S$

Pathway:

Apoptosis

Target:

Bcl-2 Family

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (120.59 mM); H₂O :

Observed Molecular Weight:

829.26


Product Description

S63845 is a potent and selective myeloid cell leukemia 1 (**MCL1**) inhibitor; binds human MCL1 with a K_d of 0.19 nM.

IC50 & Target: Kd: 0.19 nM (MCL1)^[1]

In Vitro: The pro-survival protein myeloid cell leukemia 1 (MCL1) is over expressed in many cancers. S63845 is a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. The activity of S63845 is next evaluated in a panel of eight AML cell lines: all lines are sensitive to S63845 (IC_{50} =4-233 nM)^[1].

In Vivo: S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Intravenously injected (i.v.) S63845 exerts dose-dependent anti-tumour activity in human multiple myeloma (H929 and AMO1) xenografts in immunocompromised mice, with maximal tumour growth inhibition of 114% in the AMO1 model and 103% in the H929 model. At 25 mg/kg, S63845 induces complete regression in 7 out of 8 of the mice at 100 days after treatment in the AMO1 model^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!